Next Article in Journal
Tetrapeptide Ac-HAEE-NH2 Protects α4β2 nAChR from Inhibition by Aβ
Next Article in Special Issue
Polyphenol-Mediated Autophagy in Cancer: Evidence of In Vitro and In Vivo Studies
Previous Article in Journal
Ionic Liquids Toxicity—Benefits and Threats
Previous Article in Special Issue
Mutational Landscape and Environmental Effects in Bladder Cancer
Open AccessReview

Cannabinoids and Prostate Cancer: A Systematic Review of Animal Studies

1
The Pangenomics Lab, School of Science, RMIT University, Bundoora, Victoria 3083, Australia
2
School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria 3083, Australia
3
MGC Pharmaceuticals Limited, West Perth, Western Australia 6005, Australia
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(17), 6265; https://doi.org/10.3390/ijms21176265
Received: 30 July 2020 / Revised: 26 August 2020 / Accepted: 28 August 2020 / Published: 29 August 2020
(This article belongs to the Special Issue The Effect of Dietary Factors on Cancer 2.0)
Prostate cancer is a major cause of death among men worldwide. Recent preclinical evidence implicates cannabinoids as powerful regulators of cell growth and differentiation, as well as potential anti-cancer agents. The aim of this review was to evaluate the effect of cannabinoids on in vivo prostate cancer models. The databases searched included PubMed, Embase, Scopus, and Web of Science from inception to August 2020. Articles reporting on the effect of cannabinoids on prostate cancer were deemed eligible. We identified six studies that were all found to be based on in vivo/xenograft animal models. Results: In PC3 and DU145 xenografts, WIN55,212-2 reduced cell proliferation in a dose-dependent manner. Furthermore, in LNCaP xenografts, WIN55,212-2 reduced cell proliferation by 66–69%. PM49, which is a synthetic cannabinoid quinone, was also found to result in a significant inhibition of tumor growth of up to 90% in xenograft models of LNCaP and 40% in xenograft models of PC3 cells, respectively. All studies have reported that the treatment of prostate cancers in in vivo/xenograft models with various cannabinoids decreased the size of the tumor, the outcomes of which depended on the dose and length of treatment. Within the limitation of these identified studies, cannabinoids were shown to reduce the size of prostate cancer tumors in animal models. However, further well-designed and controlled animal studies are warranted to confirm these findings. View Full-Text
Keywords: animal models; cancer; cannabinoids; cannabis; WIN55,212-2; prostate cancer animal models; cancer; cannabinoids; cannabis; WIN55,212-2; prostate cancer
Show Figures

Figure 1

MDPI and ACS Style

Singh, K.; Jamshidi, N.; Zomer, R.; Piva, T.J.; Mantri, N. Cannabinoids and Prostate Cancer: A Systematic Review of Animal Studies. Int. J. Mol. Sci. 2020, 21, 6265.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop